Cancer Family
Malignant Soft Tissue Neoplasm
CI-CAN-00000251Explore in graph →
341 active trials9 approved drugs37 evidence items
- NCIt
- C4867
Loading cancer entity…
Cancer Family
CI-CAN-00000251Explore in graph →
Clinical trials
1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (200)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05264974 | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization | suspended | Phase 1 | 18 | University of FloridaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | suspended | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05109494 | Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas | suspended | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT00079950 | Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma | suspended | Phase 2 | — | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 6, 2012 | clinicaltrials |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials